InterMune Successfully Launches European Operations and New Orphan Drug with Cloud-Based Veeva CRM and iRep

Corporate Breaking News

Home : InterMune Successfully Launches European Operations and New Orphan Drug with Cloud-Based Veeva CRM and iRep

Nov 15 2012	InterMune Successfully Launches European Operations and New Orphan Drug with Cloud-Based Veeva CRM and iRep
BARCELONA, Spain, November 15, 2012 /PRNewswire/ -- When emerging biotechnology company InterMune expanded its operations into Europe, it sought a reliable CRM solution that would help launch its orphan drug, Esbriet - the first and only treatment proven to slow disease progression in...


Source:http://www.prnewswire.com/news-releases/intermune-successfully-launches-european-operations-and-new-orphan-drug-with-cloud-based-veeva-crm-and-irep-179421041.html

Related News
» TowerJazz Presents Third Quarter 2012 Financial Results: Revenues of $155 Million; $491 Million Revenues in the First Nine Months of 2012, Growing 13% Versus $436 Million in the Same Period Last Year » Grazie a Veeva CRM cloud e a iRep, InterMune lancia con successo le attività in Europa e un nuovo farmaco orfano